Understanding cancer at the tissue level requires more than knowing which genes are expressed — it requires knowing where that expression occurs, in which cells, and in what spatial relationship to the surrounding tumor microenvironment. That spatial context is what separates a list of biomarker signals from a biological discovery. RNAscope™ spatial multiomics technology, developed by Bio-Techne, is designed to provide exactly that: in situ visualization of oncology biomarkers at single-cell resolution, directly within intact tumor tissue.
Why Spatial Context Matters in Oncology Research
Conventional bulk molecular profiling methods — RNA sequencing, qPCR, western blotting — extract signal from tissue homogenates, averaging expression across millions of cells and erasing the architectural information that defines how tumors are organized and how they interact with their microenvironment. A high average expression value for an immunosuppressive marker may reflect either diffuse low-level expression across the tumor mass or intense focal expression in a specific cell population adjacent to the invasive front. These two scenarios have entirely different biological and therapeutic implications — and bulk methods cannot distinguish between them.
RNAscope™ addresses this limitation by detecting RNA molecules directly within intact tissue sections, preserving the cellular and morphological context that gives molecular signals their meaning. Each RNA molecule appears as a discrete punctate dot within the cell in which it is expressed, enabling precise quantification at the single-molecule level while retaining full information about tissue architecture, cell morphology, and spatial relationships between cell populations.
Single-Cell Resolution in Intact Tumor Tissue
At the core of RNAscope™ is a branched DNA signal amplification chemistry that enables the detection of individual RNA molecules with high sensitivity and specificity, even in formalin-fixed, paraffin-embedded (FFPE) clinical specimens — the format in which the vast majority of oncology tissue samples are archived. This compatibility with standard clinical pathology workflows is a critical practical advantage, as it allows researchers to apply spatial RNA profiling to retrospective cohorts, clinical trial tissue banks, and biopsy archives without the need for fresh or specially preserved material.
At single-cell resolution, RNAscope™ enables:
- Cell type definition in situ: Identify and distinguish tumor cells, stromal cells, immune populations, and vascular structures based on their RNA expression profiles, without the need for cell dissociation or flow-based sorting that destroys tissue context.
- Tumor heterogeneity mapping: Characterize spatially distinct subpopulations within a single tumor section — identifying regions of different molecular subtype, differentiation state, or transcriptional activity that co-exist within the same tumor mass.
- Cell-cell interaction analysis: Examine the spatial proximity and potential signaling relationships between different cell types — for example, between PD-L1-expressing tumor cells and adjacent T cell populations — in a way that is impossible with dissociative profiling methods.
- Tumor architecture characterization: Define the spatial organization of tumors at the level of invasive fronts, necrotic cores, hypoxic regions, and perivascular niches — all structures that are biologically meaningful but invisible in bulk profiling data.
Multiomics: RNA and Protein in the Same Section
RNAscope™ is not limited to RNA detection in isolation. Through integration with protein detection methods — including immunohistochemistry (IHC) and immunofluorescence (IF) — researchers can simultaneously visualize RNA transcripts and their corresponding protein products, or combine RNA markers with established protein-based cell type classifiers, within the same tissue section.
This multiomics capability is particularly powerful for oncology applications where the relationship between transcript and protein is itself biologically informative. Post-transcriptional regulation, translational control, and protein stability differences mean that mRNA and protein levels do not always correlate. Being able to observe both within the same spatial context — in the same cell, in the same tissue section — provides a more complete picture of what is actually happening in the tumor microenvironment than either modality alone can deliver.
The combination of RNA and protein detection also enables the construction of highly multiplexed phenotyping panels that characterize individual cells simultaneously across multiple molecular dimensions, advancing the kind of deep tissue phenotyping that is increasingly required for understanding complex tumor-immune interactions and informing immunotherapy biomarker discovery.
Performance in Clinical and Research Specimens
A key measure of any spatial biology platform’s value in oncology research is its reliability across the heterogeneous, often challenging tissue samples that clinical and translational research generates. FFPE samples vary in fixation time, tissue processing conditions, and storage history — all of which can degrade RNA and compromise assay performance. RNAscope™ has been validated across a wide range of clinical specimen types, including archived FFPE tissue from diverse tumor types, and its signal amplification chemistry is specifically designed to maximize performance even on samples where RNA integrity is compromised.
This clinical robustness is reflected in the experience of researchers who have integrated RNAscope™ into their translational oncology programs. Nallasivam Palanisamy, MSc., MPhIL., PhD, Associate Professor at the Henry Ford Cancer Institute, describes the platform’s role in his research:
“RNAscope is a robust and reproducible platform that performs reliably across a wide range of clinical specimens. It has been instrumental in validating key biomarkers, defining molecular subtypes, and supporting several of our peer-reviewed publications. The technology continues to be an essential component of our spatial molecular pathology and biomarker discovery.”
This kind of cross-specimen reproducibility is essential for translational work, where findings must hold across patient cohorts with different tissue preparation histories, and for biomarker validation programs where analytical variability must be minimized to support regulatory and publication standards.
Application Spotlight: ETS Rearrangements and Tumor Heterogeneity
One illustrative example of RNAscope™’s capabilities in oncology is its application to the detection of ETS gene rearrangements — chromosomal fusions that are among the most common somatic alterations in prostate cancer and that have significant implications for molecular subtyping and therapeutic stratification. Multiplex RNAscope™ combined with immunohistochemistry enables the simultaneous mapping of ETS rearrangement status and tumor heterogeneity markers within intact prostate tumor tissue sections, delivering strong signal, low background, and clear spatial context that allows researchers to observe how rearrangement-positive and rearrangement-negative tumor cells are distributed relative to each other and to the surrounding microenvironment.
This kind of spatially resolved molecular subtyping — performed directly in tissue rather than inferred from bulk sequencing — provides information that is directly relevant to understanding the clonal architecture of tumors and the spatial organization of intratumoral heterogeneity.
Upcoming Webinar: Resolving Oncology Biomarkers and the Prostate Cancer TME
On June 17, 2026 at 8:00 AM PT, Bio-Techne will host a live webinar titled Resolve Oncology Biomarkers and Spatially Map Diversity in the Prostate Cancer Tumor Microenvironment. The session will explore in depth how RNAscope™ spatial multiomics solutions are applied to oncology research, including:
- Identification and validation of cancer biomarkers in clinical specimens
- Study of splice variants and point mutations in situ
- Interrogation of the tumor microenvironment at single-cell resolution
- Applications in cell therapy and antibody therapeutic program support
The webinar represents a practical opportunity for oncology researchers, translational scientists, and spatial biology practitioners to see the technology in action and understand how it can be integrated into their own research programs.
A Platform Built for Oncology Discovery
As the field moves toward increasingly spatially resolved approaches to understanding cancer — driven by the recognition that tumor behavior is shaped as much by context as by intrinsic molecular characteristics — the tools researchers use to study that context become correspondingly important. RNAscope™ occupies a well-established position in this landscape: a platform with deep clinical validation, proven performance across tissue types, and the multiomics flexibility to grow alongside the questions oncology research is asking.
For teams working on biomarker discovery, therapeutic target validation, tumor microenvironment characterization, or translational companion diagnostics, RNAscope™ provides the spatial molecular resolution that bulk methods cannot deliver — and the clinical specimen compatibility that makes that resolution actionable in real research settings.